NCT06438627 2024-07-16Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 TrialSun Yat-sen UniversityPhase 3 Recruiting164 enrolled
NCT05854849 2023-05-11Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPCSun Yat-sen UniversityPhase 3 Recruiting244 enrolled